Kronos, Invivoscribe to develop CDx for entospeltinib

2019 12 11 18 50 5654 Leukemia Aml 400

Kronos Bio and Invivoscribe on Tuesday announced a partnership to develop a companion diagnostic (CDx) test for use with Kronos’ entospletinib, an investigational treatment for NPM1-mutated acute myeloid leukemia (AML).

The CDx will screen for the NPM1 mutation, which is present in approximately one-third of all patients with AML.

The efficacy and safety of entospletinib is being studied in Kronos Bio's ongoing Phase 3 registrational AGILITY study. About 180 adults newly diagnosed with NPM1-mutated AML are either receiving entospletinib or a placebo, in combination with standard induction and consolidation chemotherapy. The trial aims to measure residual disease-negative complete response.

Page 1 of 12
Next Page